AKT1 E17K Mutation and B-cell Lymphoid Leukaemia
Author Information
Author(s): Mahmoud I S, Sughayer M A, Mohammad H A, Eshtayeh A A, Awidi A S, EL-Khateeb M S, Ismail S I
Primary Institution: University of Jordan
Hypothesis
Is the E17K mutation in the AKT1 gene a significant event in B-cell-derived lymphoid leukaemias?
Conclusion
The E17K mutation in the AKT1 gene is not a major event in B-cell-derived lymphoid leukaemias.
Supporting Evidence
- The mutation E17K/AKT1 was not detected in any of the 87 specimens.
- Previous studies suggested the mutation might be significant in other cancers, but not in B-cell leukaemias.
- Further research is needed to explore the mutation in other types of leukaemia.
Takeaway
The study looked for a specific mutation in blood cancer but found it wasn't there, suggesting it doesn't play a big role in these types of leukaemia.
Methodology
DNA was extracted from blood samples and the AKT1 gene was sequenced to check for the E17K mutation.
Limitations
The study had a small sample size and did not include T-lineage cells of ALL.
Participant Demographics
Patients were Jordanian, with 45 CLLs, 38 ALLs, and 4 PLLs.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website